Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 63 of 2838 for:    Pancreatic Cancer

Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02550847
Recruitment Status : Unknown
Verified April 2016 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : September 16, 2015
Last Update Posted : April 14, 2016
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Condition or disease Intervention/treatment
Pancreatic Cancer Device: The imaging biomarkers determined by MR-PET

Detailed Description:
The results of MR/PET will be compared prospectively to dedicated MDCT or MR imaging, pathologic results, and clinical outcomes to assess the value of MR/PET in pancreatic cancers.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer
Study Start Date : August 2014
Estimated Primary Completion Date : April 2016
Estimated Study Completion Date : August 2016

Resource links provided by the National Library of Medicine



Intervention Details:
  • Device: The imaging biomarkers determined by MR-PET
    The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.


Primary Outcome Measures :
  1. The tumor recurrence rate after operation at 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. The overall survival after operation at 6 months [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will include 100 consecutive patients (around 100 newly diagnosed patients per year at NTUH) presenting with suspect pancreatic cancer for treatment.
Criteria

Inclusion Criteria:

  1. Diagnosed as pancreatic cancer
  2. Between 20~90 years old
  3. ECOG 0-2
  4. Normal renal function
  5. Measurable tumor size (>1cm)

Exclusion Criteria:

  1. Contraindication for MRI exam
  2. Claustrophobia
  3. Renal insufficiency
  4. Other malignancy
  5. Pregnancy and lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02550847


Contacts
Layout table for location contacts
Contact: Ting-Fang Shih, MD +886-2-23123456 ext 65568 ttfshih@ntu.edu.tw

Locations
Layout table for location information
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Ting-Fang Shih, MD    +886-2-23123456 ext 65568    ttfshih@ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Ting-Fang Shih, MD Department of Medical Imaging, National Taiwan University Hospital

Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT02550847     History of Changes
Other Study ID Numbers: 201407052MINC
First Posted: September 16, 2015    Key Record Dates
Last Update Posted: April 14, 2016
Last Verified: April 2016

Keywords provided by National Taiwan University Hospital:
MR/PET
pancreatic cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases